PDF herunterladen
Aktuelle Rheumatologie 2021; 46(02): 143-148
DOI: 10.1055/a-1340-0000
Übersichtsarbeit

Risikostratifizierung für Therapieentscheidungen bei Rheumatoider Arthritis

Risk Stratification for Treatment Decisions in Rheumatoid Arthritis
Katinka Albrecht 
1   Deutsches Rheuma-Forschungszentrum, Programmbereich Epidemiologie und Versorgungsforschung, Berlin, Deutschland
,
Anne Regierer 
1   Deutsches Rheuma-Forschungszentrum, Programmbereich Epidemiologie und Versorgungsforschung, Berlin, Deutschland
,
Anja Strangfeld
1   Deutsches Rheuma-Forschungszentrum, Programmbereich Epidemiologie und Versorgungsforschung, Berlin, Deutschland
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Zusammenfassung

Um für die Behandlung der rheumatoiden Arthritis unter der Vielzahl an zugelassenen krankheitsmodifizierenden Antirheumatika die geeignete Therapie auszuwählen, werden Patienten anhand ihres Risikos für einen ungünstigen Krankheitsverlauf stratifiziert. Die Auswahl geeigneter Parameter zur Risikostratifizierung werden in dieser Übersichtsarbeit dargestellt. Beim heutigen Therapieziel einer Remission sind hohe Krankheitsaktivität, Funktionseinschränkungen, Begleiterkrankungen und Übergewicht relevante Faktoren für einen ungünstigen Verlauf. Weitere Einflussfaktoren auf die Therapieentscheidung wie Begleiterkrankungen, Infektionsrisiko und spezielle Risikokonstellationen wie vorausgegangene schwerwiegende Infektionen oder Malignome werden in diesem Artikel diskutiert.

Abstract

In order to select the appropriate drug for the treatment of rheumatoid arthritis, patients are stratified according to their risk of an unfavourable course. This review paper presents the selection of suitable parameters for risk stratification. In the light of the current therapeutic target of remission, relevant factors for an unfavourable course include high disease activity, functional limitations and the presence of comorbidities and obesity. Also this article discusses further factors influencing treatment decisions, e. g. concomitant diseases, risk of infection and special risk constellations such as previous serious infections or malignancies.

Schlüsselwörter

DMARDs - biologics - disease activity - infections - comorbidity

Key words

DMARDs - Biologika - Krankheitsaktivität - Infektionen - Komorbidität


Publikationsverlauf

Artikel online veröffentlicht:
09. Februar 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Fiehn C, Holle J, Iking-Konert C. et al. S2e-Leitlinie: Therapie der rheumatoiden Arthritis mit krankheitsmodifizierenden Medikamenten. Z Rheumatol 2018; 77: 35-53
    CrossrefPubMedSuche in Google Scholar
  • 2 Smolen JS, Landewe RBM, Bijlsma JWJ. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020; 79: 685-699
    CrossrefPubMedSuche in Google Scholar
  • 3 Albrecht K, Zink A. Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: a review of data from randomized clinical trials and cohort studies. Arthritis Res Ther 2017; 19: 68
    CrossrefPubMedSuche in Google Scholar
  • 4 Baganz L, Richter A, Albrecht K. et al. Are prognostic factors adequately selected to guide treatment decisions in patients with rheumatoid arthritis? A collaborative analysis from three observational cohorts. Semin Arthritis Rheum 2019; 48: 976-982
    CrossrefPubMedSuche in Google Scholar
  • 5 Singh JA, Saag KG, Bridges SL. et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol 2016; 68: 1-26
    CrossrefPubMedSuche in Google Scholar
  • 6 Castrejon I, Dougados M, Combe B. et al. Prediction of Remission in a French Early Arthritis Cohort by RAPID3 and other Core Data Set Measures, but Not by the Absence of Rheumatoid Factor, Anticitrullinated Protein Antibodies, or Radiographic Erosions. J Rheumatol 2016; 43: 1285-1291
    CrossrefPubMedSuche in Google Scholar
  • 7 Lautenschlager J, Mau W, Kohlmann T. et al. Vergleichende Evaluation einer deutschen Version des Health Assessment Questionnaires (HAQ) und des Funktionsfragebogens Hannover (FFbH). Z Rheumatol 1997; 56: 144-155
    CrossrefPubMedSuche in Google Scholar
  • 8 Meissner Y, Zink A, Kekow J. et al. Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis. Arthritis Res Ther 2016; 18: 183
    CrossrefPubMedSuche in Google Scholar
  • 9 Meissner Y, Richter A, Manger B. et al. Serious adverse events and the risk of stroke in patients with rheumatoid arthritis: results from the German RABBIT cohort. Ann Rheum Dis 2017; 76: 1583-1590
    CrossrefPubMedSuche in Google Scholar
  • 10 Michelsen B, Kristianslund EK, Sexton J. et al. Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study. Ann Rheum Dis 2017; 76: 1906-1910
    CrossrefPubMedSuche in Google Scholar
  • 11 Jani M, Barton A, Hyrich K. Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification?. Curr Opin Rheumatol 2019; 31: 285-292
    CrossrefPubMedSuche in Google Scholar
  • 12 Strangfeld A, Eveslage M, Schneider M. et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?. Ann Rheum Dis 2011; 70: 1914-1920
    CrossrefPubMedSuche in Google Scholar
  • 13 Richter A, Listing J, Schneider M. et al. Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis. Ann Rheum Dis 2016; 75: 1667-1673
    CrossrefPubMedSuche in Google Scholar
  • 14 Zink A, Manger B, Kaufmann J. et al. Evaluation of the RABBIT Risk Score for serious infections. Ann Rheum Dis 2014; 73: 1673-1676
    CrossrefPubMedSuche in Google Scholar
  • 15 Rutherford AI, Subesinghe S, Hyrich KL. et al. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis 2018; 77: 905-910
    CrossrefPubMedSuche in Google Scholar
  • 16 Curtis JR, Xie F, Yang S. et al. Risk for Herpes Zoster in Tofacitinib-Treated Rheumatoid Arthritis Patients With and Without Concomitant Methotrexate and Glucocorticoids. Arthritis Care Res (Hoboken) 2019; 71: 1249-1254
    CrossrefPubMedSuche in Google Scholar
  • 17 Subesinghe S, Rutherford AI, Byng-Maddick R. et al. Biologic prescribing decisions following serious infection: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis. Rheumatology (Oxford) 2018; 57: 2096-2100
    CrossrefPubMedSuche in Google Scholar
  • 18 Au K, Reed G, Curtis JR. et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70: 785-791
    CrossrefPubMedSuche in Google Scholar
  • 19 Krüger K, Nusslein H. Kardiovaskuläre Komorbiditäten bei rheumatoider Arthritis. Z Rheumatol 2019; 78: 221-227
    CrossrefPubMedSuche in Google Scholar
  • 20 Listing J, Strangfeld A, Kekow J. et al. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?. Arthritis Rheum 2008; 58: 667-677
    CrossrefPubMedSuche in Google Scholar
  • 21 Baniaamam M, Paulus WJ, Blanken AB. et al. The effect of biological DMARDs on the risk of congestive heart failure in rheumatoid arthritis: a systematic review. Expert Opin Biol Ther 2018; 18: 585-594
    CrossrefPubMedSuche in Google Scholar
  • 22 Wadstrom H, Frisell T, Askling J. et al. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden. JAMA Intern Med 2017; 177: 1605-1612
    CrossrefPubMedSuche in Google Scholar
  • 23 Mercer LK, Askling J, Raaschou P. et al. Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. Ann Rheum Dis 2017; 76: 386-391
    CrossrefPubMedSuche in Google Scholar
  • 24 Mercer LK, Regierer AC, Mariette X. et al. Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project. Ann Rheum Dis 2017; 76: 2025-2030
    CrossrefPubMedSuche in Google Scholar
  • 25 Silva-Fernandez L, Lunt M, Kearsley-Fleet L. et al. The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis. Rheumatology (Oxford) 2016; 55: 2033-2039
    CrossrefPubMedSuche in Google Scholar
  • 26 Raaschou P, Frisell T, Askling J. et al. TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis 2015; 74: 2137-2143
    CrossrefPubMedSuche in Google Scholar
  • 27 Regierer AC, Strangfeld A. Rheumatoid arthritis treatment in patients with a history of cancer. Curr Opin Rheumatol 2018; 30: 288-294
    CrossrefPubMedSuche in Google Scholar
  • 28 Chatzidionysiou K, Delcoigne B, Frisell T. et al. How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers. RMD Open 2020; 6 (02) e001363
    CrossrefPubMedSuche in Google Scholar
  • 29 Schäfer M, Meissner Y, Kekow J. et al. Obesity reduces the real-world effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis. Rheumatology (Oxford) 2020; 59: 1916-1926
    CrossrefPubMedSuche in Google Scholar
  • 30 Luque Ramos A, Hoffmann F, Albrecht K. et al. Transition to adult rheumatology care is necessary to maintain DMARD therapy in young people with juvenile idiopathic arthritis. Semin Arthritis Rheum 2017; 47: 269-275
    CrossrefPubMedSuche in Google Scholar
  • 31 Luque Ramos A, Redeker I, Hoffmann F. et al. Comorbidities in Patients with Rheumatoid Arthritis and Their Association with Patient-reported Outcomes: Results of Claims Data Linked to Questionnaire Survey. J Rheumatol 2019; 46: 564-571
    CrossrefPubMedSuche in Google Scholar
  • 32 Luque Ramos A, Albrecht K, Zink A. et al. Rheumatologic care of nursing home residents with rheumatoid arthritis: a comparison of the year before and after nursing home admission. Rheumatol Int 2017; 37: 2059-2064
    CrossrefPubMedSuche in Google Scholar